Rapid Urease Test Developed to Diagnose H. pylori Infection in Asymptomatic Patients
|
By LabMedica International staff writers Posted on 25 Oct 2011 |
|
A new rapid urease assay offers high sensitivity and accuracy for diagnosis of Helicobacter pylori in untreated patients.
Dyspepsia is a multifaceted range of symptoms related to the upper gastrointestinal (GI) tract. Population-based surveys have shown dyspepsia to be a global problem with 15% to 40% of the populace complaining of upper GI symptoms. Although several guidelines recommend an initial noninvasive “test and treat” approach for the diagnosis of H. pylori in primary care if patients do not complain of acute symptoms and are younger than 45-50 years, many dyspeptic patients are still referred for endoscopy.
In a recent cohort of US patients, about one-third of all upper endoscopic procedures were performed for patients with dyspeptic symptoms without alarm symptoms. In some countries, the high prevalence of gastric cancer in young dyspeptic patients also makes early endoscopy an important feature of dyspepsia management.
Endoscopic tests for H. pylori have progressed in the past 10 years and one area of growth has been the speed with which the rapid urease test (RUT) can be read. A new urease test, the Urea ultrafast-test--UFT 300, developed by ABS Advanced Biomedical Systems (Cernusco sul Naviglio, Italy) can be read in five minutes. The test, which was approved in the European Union, has the potential to simplify the clinical management further by allowing the result of the test to be included in the endoscopy report when patient leaves the endoscopy unit.
To assess the diagnostic accuracy of this new rapid urease test to diagnose H. pylori infection in untreated patients using an independent external reference standard, scientists from the department of internal medicine and gastroenterology at the University of Bologna (Italy) examined 1,000 consecutive dyspeptic patients and demonstrated that the new rapid urease UFT300 test offers high sensitivity (94.5%) and accuracy (100%), with a considerably shorter time period to read both a positive and a negative test.
The study was published January 2010 in the journal Alimentary Pharmacology & Therapeutics journal.
Related Links:
ABS Advanced Biomedical Systems
University of Bologna
Dyspepsia is a multifaceted range of symptoms related to the upper gastrointestinal (GI) tract. Population-based surveys have shown dyspepsia to be a global problem with 15% to 40% of the populace complaining of upper GI symptoms. Although several guidelines recommend an initial noninvasive “test and treat” approach for the diagnosis of H. pylori in primary care if patients do not complain of acute symptoms and are younger than 45-50 years, many dyspeptic patients are still referred for endoscopy.
In a recent cohort of US patients, about one-third of all upper endoscopic procedures were performed for patients with dyspeptic symptoms without alarm symptoms. In some countries, the high prevalence of gastric cancer in young dyspeptic patients also makes early endoscopy an important feature of dyspepsia management.
Endoscopic tests for H. pylori have progressed in the past 10 years and one area of growth has been the speed with which the rapid urease test (RUT) can be read. A new urease test, the Urea ultrafast-test--UFT 300, developed by ABS Advanced Biomedical Systems (Cernusco sul Naviglio, Italy) can be read in five minutes. The test, which was approved in the European Union, has the potential to simplify the clinical management further by allowing the result of the test to be included in the endoscopy report when patient leaves the endoscopy unit.
To assess the diagnostic accuracy of this new rapid urease test to diagnose H. pylori infection in untreated patients using an independent external reference standard, scientists from the department of internal medicine and gastroenterology at the University of Bologna (Italy) examined 1,000 consecutive dyspeptic patients and demonstrated that the new rapid urease UFT300 test offers high sensitivity (94.5%) and accuracy (100%), with a considerably shorter time period to read both a positive and a negative test.
The study was published January 2010 in the journal Alimentary Pharmacology & Therapeutics journal.
Related Links:
ABS Advanced Biomedical Systems
University of Bologna
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
Latest Microbiology News
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read more
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
Technology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
